Sanofi reported that its GLP-1, lixisenatide, bested the GLP-1 Byetta, exenatide, in a head to head trial of type 2 diabetes patients. The lixisenatide arm experienced many fewer hypoglycemia events (about 6-fold fewer).
Sanofi's GLP-1 drug when approved will take on Novo Nordisk's Victoza and Amylin/Lilly's Byetta. It's being billed as a blockbuster candidate by many analysts. This is especially true with the world's diabetic population expected to explode from 285 million to more than 435 million in the next 20 years - keep eating that quality Western diet.
Sanofi is playing catch up with its GLP-1 version so this type of result with a putative direct competitor product is a good shot in the arm.
Posted by Bruce Lehr Feb 2nd 2011.